⌕
Edgewise Therapeutics · EWTX · Nasdaq
Tenet 68 · Solid
Compare
$45.93+0.24%At closeTenet 68 · Solid
$45.93+0.11 (+0.24%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Edgewise Therapeutics (EWTX) Stock

Edgewise Therapeutics (EWTX) closed at $45.93 on Nov 13, 2026; its Tenet Score is 68 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

29 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$45.93
Nov 13, 2026
Market cap
$5.0B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
5.5×
price ÷ earnings
52-week range
19.76 – 48.78
low → high
Tenet Score
68/100
Solid · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Edgewise Therapeutics Inc scores 68/100. Solid. Strongest on financial health and value, quality is the soft spot, trading at 6× earnings versus 409 Healthcare peers. Insufficient inputs: Tenet 68 is built from 3 of 4 pillars, from 45% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
68/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
80
Quality
37
Health
87
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueBQualityDHealthBGrowth—MomentumA
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
3.1×
price to book value
P/S
—
no P/S on file
ROE
92%
return on equity
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
12.30
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Edgewise Therapeutics Inc

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystroph…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 68 US ETFs · top wrappers by weightSee all ETFs holding EWTX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Edgewise Therapeutics in?

Edgewise Therapeutics is in the Healthcare sector and the Drugs industry.

What is Edgewise Therapeutics' Tenet Score?

Edgewise Therapeutics' Tenet Score is 68 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.